Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04140526
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:46.367264+00:00
Published At
2025-05-23T00:00:00+00:00
Record Updated At
2025-05-23
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Non Small Cell Lung Cancer", "Advanced Solid Tumor", "Metastatic Melanoma", "Metastatic Head and Neck Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Colorectal Cancer", "Sarcomas", "Metastatic Prostate Cancer", "Ovarian Cancer", "Small Cell Lung Cancer", "Metastatic Breast Cancer", "Pancreas Cancer", "Gastric Cancer", "Esophageal Cancer", "Gastroesophageal Junction Adenocarcinoma", "Cervical Cancer", "Adenoid Cystic Carcinoma", "Salivary Gland Cancer", "Urothelial Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-05-23"
protocolSection.identificationModule.nctId
"NCT04140526"
protocolSection.identificationModule.officialTitle
"Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Non Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Advanced Solid Tumor (protocolSection.conditionsModule.conditions)
  • Metastatic Melanoma (protocolSection.conditionsModule.conditions)
  • Metastatic Head and Neck Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Colorectal Cancer (protocolSection.conditionsModule.conditions)
  • Sarcomas (protocolSection.conditionsModule.conditions)
  • Metastatic Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Breast Cancer (protocolSection.conditionsModule.conditions)
  • Pancreas Cancer (protocolSection.conditionsModule.conditions)
  • Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Adenoid Cystic Carcinoma (protocolSection.conditionsModule.conditions)
  • Salivary Gland Cancer (protocolSection.conditionsModule.conditions)
  • Urothelial Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.